Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification: a Prospective Multicenter Umbrella Clinical Study（FEMUS）

Endometrial cancer (EC) stands among the most common gynecological malignancies in developed countries and regions, with a notable trend toward younger age at onset. Correspondingly, the demand for fertility-sparing treatment (FST) has been increasingly prominent among young EC patients. High-potency progestogens remain the sole therapeutic option recommended by international guidelines for this patient population; however, approximately 30% of patients exhibit no response to such treatment.
The concept of EC molecular subtyping, proposed by The Cancer Genome Atlas (TCGA) in 2013, has revolutionized the diagnosis and management of EC. EC subtypes with distinct molecular features demonstrate substantial differences in biological behaviors and responses to pharmacotherapeutic interventions. Nevertheless, the role of molecular subtyping in guiding FST decision-making-both in terms of its applicability and specific mechanisms-remains an unmet research need worldwide.
Notably, the POLE-mutant and microsatellite instability-high (MSI-H) subtypes display the highest sensitivity to immune checkpoint inhibitors, underscoring the clinical value of exploring their utility in FST. The no specific molecular profile (NSMP) subtype is sensitive to progestogens but lacks reliable predictive biomarkers-accurate pre-treatment prediction would enable tailored treatment selection, shorten treatment duration, and enhance therapeutic outcomes. In contrast, the p53-abnormal (p53abn) subtype is associated with a poor prognosis, and FST is therefore not recommended for this subgroup.
Building on the aforementioned background and our research team's preliminary clinical findings, this project focuses on the field of FST for EC. To address the current challenges-including narrow indications, limited treatment options, suboptimal efficacy, and the absence of precise personalized regimens-we aim to conduct the world's first prospective multicenter umbrella trial based on EC molecular subtyping. Optimal novel diagnostic and therapeutic protocols will be developed for each molecular subtype, with the goals of optimizing existing FST strategies, improving FST efficacy and reproductive outcomes, expanding eligible indications, and providing high-quality clinical evidence for molecular subtype-guided FST in EC, thereby advancing the overall effectiveness of FST for EC patients.

Start Date15 Dec 2025

Sponsor / Collaborator

Fudan University

IRCT20250225064853N5

/ SuspendedPhase 3IIT

Evaluating the Effect of Medroxyprogesterone on Reducing Size and Symptoms of Endometrial Polyps in Patients with Endometrial Polyps: A Randomized Controlled Trial with Placebo Group

Start Date21 Nov 2025

Sponsor / Collaborator

Isfahan University of Medical Sciences

IRCT20210730052016N2

/ SuspendedPhase 3IIT

Investigating the effect of Medroxyprogesterone on blood gases and short-term outcomes in COPD patients undergoing Non-Invasive Ventilation(NIV)

Start Date21 Oct 2025

Sponsor / Collaborator

Hamedan University of Medical Sciences

100 Clinical Results associated with Medroxyprogesterone Acetate

100 Translational Medicine associated with Medroxyprogesterone Acetate

100 Patents (Medical) associated with Medroxyprogesterone Acetate

7,660

Literatures (Medical) associated with Medroxyprogesterone Acetate

01 Feb 2026·THERIOGENOLOGY

A novel therapeutic approach: The effect of letrozole-assisted synchronization on reproductive performance in suckling ewes during the non-breeding season

Article

Author: Gözer, Ahmet ; Kaya, Ufuk ; Abay, Murat ; Arslanhan, Ebru ; Kara, Filiz ; Yüksel, Murat ; Uyanık, Gökhan

The aim of the present study was to investigate the effect of letrozole treatment on the success of a progesterone-based synchronization protocol and fertility parameters in suckling Awassi ewes during the anoestrus period. One hundred and five multiparous, suckling Awassi ewes were used. Ewes (n = 105) were randomly divided into three groups as Control (n = 35), LET-4 (n = 35) and LET-0 (n = 35). Four days before the synchronization protocol (D-4), letrozole at a dose of 1 mg/kg was administered subcutaneously (s.c.) to the LET-4 group, while the LET-0 group received it on the day of protocol initiation (D0). The control group received 1 mL of benzyl alcohol s.c. at both time points as a placebo. Subsequently, intravaginal sponges containing 60 mg medroxyprogesterone acetate were inserted into all ewes (D0). The sponges were kept in the vagina for 7 days and 500 IU eCG and 75 μg d-cloprostenol were administered intramuscularly on the day the sponges were removed. Blood samples were taken for measurement of serum E₂, FSH and P₄ before sponge insertion (D-4 and D-2), on the day of sponge insertion (D0), after sponge insertion (D2 and D4), at mating (DM) and post-mating days (DPM-7, 14, 21, 35 and 50). Pregnancy was diagnosed by transrectal ultrasonography at DPM-21, 35, and 50. The overall mean serum FSH concentrations, calculated across all sampling days, were significantly higher in the LET-4 group (27.68 ± 1.56 mIU/mL) than in LET-0 (21.85 ± 0.87 mIU/mL) and Control (18.54 ± 0.91 mIU/mL) (P < 0.001). Subsequent to the FSH elevation, serum E₂ levels at the time of mating were also significantly higher in LET-4 (22.24 ± 1.20 pg/mL) than in LET-0 (14.47 ± 0.92 pg/mL) and Control (10.77 ± 0.69 pg/mL) (P < 0.001). Post-mating P₄ concentrations were likewise significantly elevated in the LET-4 group (3.79 ± 0.24 ng/mL) compared to LET-0 (3.29 ± 0.24 ng/mL) and Control (2.78 ± 0.24 ng/mL) groups (P < 0.001). Estrus rate was highest in the LET-4 group (90.62 %) compared to LET-0 (68.57 %) and Control (57.57 %) (P = 0.010). Pregnancy rate on day 50 was significantly greater in LET-4 (59.37 %) than in LET-0 (37.14 %) and Control (27.27 %) (P = 0.027). Fecundity rate was also highest in LET-4 (87.50 %) compared to LET-0 (57.14 %) and Control (33.33 %) (P < 0.001). No significant differences were observed among groups in litter size, twinning or pregnancy losses rates (P > 0.05). In conclusion, letrozole administration four days before the synchronization protocol significantly enhanced reproductive performance in suckling ewes during the non-breeding season. These results suggest that this approach could be a promising alternative strategy to improve protocol success without resorting to early weaning.

01 Jan 2026·POULTRY SCIENCE

Effect of apparent metabolizable energy and sex on predictive models for growth performance, carcass traits, gut characteristics, and pellet quality in broiler chicks

Article

Author: Rahmatnejad, Enayat ; Hassan, Mahya Pahlavan ; Mohammadi, Mohammad Hossein

This study aimed to investigate the effects of different dietary apparent metabolizable energy (AMEn) levels and bird sex on prediction models for growth performance, carcass traits, gut characteristics, and physical pellet quality (PPQ) of starter and finisher diets in broiler chicks over a 43-d period. A total of 700 Hubbard Flex feather-sexed broiler chicks were randomly assigned to 10 treatment groups (five replicates with 14 birds/replicate) within a completely randomized design across three feeding phases: starter (1 to 14 days), grower (15 to 28 days), and finisher (29 to 43 days). Diets were arranged factorially (5 × 2) with five levels of AMEn (2850, 2950, 3050, 3150, and 3250 kcal/kg), and two sexes (male and female). The results indicated a significant interaction between dietary AMEn and sex for growth performance, carcass traits, and gut characteristics, except for carcass yield, abdominal fat pad (AFP), and the relative weight of liver and leg (P < 0.05). In both sexes, birds fed diets containing 3050 kcal/kg AMEn across the starter, grower, and finisher phases showed the best growth performance from day 1 to 42 compared to other treatments (P < 0.05). Additionally, providing broilers with dietary AMEn levels higher than 3050 kcal/kg did not result in significant improvements in growth performance and carcass yield. Dietary AMEn significantly affected carcass yield, and sex had a significant impact on AFP at day 43 (P < 0.05). Birds receiving 2850 kcal/kg diets had the lowest carcass yield, whereas female broilers showed a higher AFP than males (P < 0.05). Dietary AMEn significantly influenced the pellet durability index (PDI) of finisher feeds (P < 0.05), with the 3050 kcal/kg diet exhibiting the highest PDI among all treatments (P < 0.05). In conclusion, increasing dietary AMEn levels beyond 3050 kcal/kg did not lead to linear improvements in growth performance, carcass traits, gut organ weights, and pellet quality in both male and female broiler chickens.

01 Jan 2026·METHODS

Carboxyl-PEG modified Fe3O4 nanoparticles as an ultrasensitive SERS substrate for multiplex detection of exogenous hormones related to endometrial cancer

Article

Author: Sun, Haizhu ; Zhao, Yinghan ; Qiu, Xiaohong ; Gao, Jiayin ; Liu, Yan ; Chen, Biqing

Traditional surface-enhanced Raman scattering (SERS) technology often struggles to achieve high-precision discrimination in the simultaneous detection of multiple exogenous hormones due to complex spectral overlap and matrix interference, limiting its application in trace analyte analysis within complex matrices (e.g., biological samples). This study developed a SERS substrate based on carboxyl-terminal polyethylene glycol (PEG)-modified iron oxide (Fe₃O₄) nanoparticles (Fe₃O₄@PEG), integrated with artificial intelligence (AI)-driven high-throughput spectral analysis algorithms. This approach successfully enabled ultrasensitive detection and precise discrimination of multiple typical exogenous hormonal drugs, including tamoxifen, drospirenone, cyproterone acetate, medroxyprogesterone acetate, estradiol ester derivatives, and dydrogesterone. By optimizing the surface enhancement effect of Fe₃O₄@PEG nanocomposites and employing machine learning models (e.g., convolutional neural networks, CNN) for collaborative analysis, the weak Raman fingerprint features of target hormones in complex mixtures were effectively extracted and classified, achieving a detection limit at the corresponding to 10^-7-10^-8 mg/mL level. In matrix-spiked serum and urine samples, which mimic complex biological matrices validations, the AI-SERS platform demonstrated exceptional performance in the identification and quantitative analysis of target exogenous hormones. This research provides an intelligent analytical strategy for rapid and highly sensitive detection of multiple trace exogenous hormones in complex matrices.

News (Medical) associated with Medroxyprogesterone Acetate

18 Dec 2025

·www.drugs.com

FDA Adds Brain Tumor Warning to Depo-Provera Birth Control Shot

THURSDAY, Dec. 18, 2025 (HealthDay News — The U.S. Food and Drug Administration (FDA) approved a new safety warning for Depo-Provera , a widely used birth control shot made by Pfizer , alerting patients to a possible risk for a type of brain tumor called meningioma. The agency signed off last week on a label update for two versions of the Depo- Provera injection, requiring new language about the tumor risk. The decision comes as Pfizer faces lawsuits from more than 1,000 women who say the company knew about the risks and didn’t warn them. Depo-Provera is a hormone-based birth control shot given once every three months. It contains progestin, a synthetic version of the hormone progesterone. About 1 in 4 sexually active women in the United States have used the shot at some point, according to the U.S. Centers for Disease Control and Prevention (CDC). Use is especially common among Black women, who receive it at nearly twice the national rate. Meningiomas are usually not cancerous, but, depending on their size and location, they can cause serious health problems. Each year, about 39,000 meningiomas are diagnosed in the U.S., data show. In court filings, Pfizer said it first became aware of a possible link between Depo-Provera and meningioma in 2023. The company asked the FDA in early 2024 to add a warning to the drug’s label. That request was initially denied, with the FDA saying existing studies did not clearly support a warning for all products containing medroxyprogesterone acetate (MPA), the drug used in the shot. Pfizer later revised its request and resubmitted it in June 2025. This time, the FDA agreed. In a letter approving the change, the agency said the update “provides for the addition of information related to meningioma risk” on the labels for Depo-Provera CI and Depo-Subq Provera 104 . In a statement, Pfizer said the “label update reflects a recent decision by the FDA to approve the warning, which the agency had earlier denied.” The statement also said: “Pfizer stands behind the safety and efficacy of Depo-Provera, which has been used by millions of women worldwide and remains an important treatment option for women seeking to manage their reproductive health.” Attorneys representing women suing Pfizer welcomed the move, saying the new warning will help patients make better-informed choices. Regulators in other countries had already acted. In 2024, European and Canadian health agencies added meningioma warnings to high-dose hormone products like Depo-Provera. South Africa followed with similar guidance earlier this year. A U.S. judge has not yet ruled on whether the lawsuit against Pfizer will move forward. Sources NBC News, Dec. 16, 2025

Patent Infringement

18 Dec 2025

·www.pharmaceutical-technology.com

FDA approves meningioma label warning on Pfizer’s contraceptive injection

The FDA has approved a label change to Pfizer’s contraceptive injection, Depo Provera, which will warn prescribers and patients of the increased risk of meningioma associated with the drug’s use. Image credit: ShU studio via ShutterStock.com. The US Food and Drug Administration (FDA) has approved a label change to Pfizer’s injectable contraceptive, Depo-Provera (medroxyprogesterone acetate), which will warn users of their increased risk of meningioma. The FDA’s crackdown on Depo-Provera comes amid a highly publicised legal battle between Pfizer and more than 2,000 women, who are currently suing the New York-based pharma after they developed meningiomas they believe are caused by exposure to the contraceptive. Depo-Provera contains progestin, a synthetic form of the sex hormone progesterone. While it has been on the contraceptive market since the early 1990s, a recent study published in the British Medical Journal has uncovered the heightened risk of intracranial meningioma associated with the jab’s prolonged use. A December 2023 National Health Statistics Report estimates that nearly 24.5% of all sexually experienced women in the US have used Depo-Provera at some point between 2015 and 2019. Meningiomas are tumours that grow in the protective membranes that coat the brain and spinal cord. Patients with meningiomas commonly experience headaches, seizures, weakness and numbness. Though they are typically benign, they can have a significant impact on a patient’s quality of life (QoL). In some cases, they are also life-threatening. The FDA’s call to enforce a label warning for Depo-Provera marks a potential turn in the agency’s stance on the contraceptive, as it previously rejected Pfizer’s label update application in 2024. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence FDA clampdown could spell legal trouble for Pfizer Throughout the legal battle between Pfizer and the 2,000-plus plaintiffs, claims against the big pharma have largely centred around its failure to warn doctors and patients of the risk of meningioma associated with Depo-Provera’s use. Pfizer has previously argued in court that the FDA had prohibited it from including a label warning on Depo-Provera, thus prompting the company to request the dismissal of such lawsuits. However, Ben Martin, founder of the drug and medical device litigation group, Ben Martin Law Group, told Pharmaceutical Technology that this defence may no longer hold up in court. Martin said: “This ‘impossibility’ pre-emption argument should now fail given that a warning was not only possible but that the FDA is now requiring such a warning. “Pfizer has known for decades that there may be an association between the use of Depo-Provera and the development of meningiomas.” In his eyes, the New York-based pharma “could and should have performed studies exploring this link”, which would have uncovered the greater risk of developing meningioma with the use of Depo-Provera versus not using it. Bryan Aylstock  of  Aylstock Witkin Kreis & Overholtz, Christopher Seeger of Seeger Weiss, and Ellen Relkin of Weitz & Luxenberg, co-lead counsel in the Depo-Provera Products Liability Litigation echoed this sentiment, adding that Pfizer’s misconduct has caused “lasting neurological damage, vision loss and death” in women who developed brain tumours caused by Depo-Provera. “We applaud the FDA in finally requiring this label change to better inform and protect women,” they concluded. Pharmaceutical Technology Excellence Awards - Nominations Closed Nominations are now closed for the Pharmaceutical Technology Excellence Awards . A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact. Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing , Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines. Discover the Impact

Drug ApprovalPatent Infringement

18 Nov 2025

·www.einpresswire.com

Pfizer Joined in a Depo-Provera Meningioma Case in California State Court

Research and legal claims highlight alleged mutagenic risks of Depo-Provera, linking long-term use to increased meningioma frequency and recurrence It is important to examine why physicians continue prescribing Depo-Provera and Medroxyprogesterone despite the literature linking them to this serious injury.” — Greg Vigna, MD, JD LOS ANGELES, CA, UNITED STATES, November 17, 2025 / EINPresswire.com / -- “To this day, Pfizer does not state in its warnings that Depo-Provera is mutagenic, despite clear evidence of a dose-dependent increased risk of meningiomas in women injected with the drug for a year or more, and of a specific mutational tendency linked to its use,” states Greg Vigna, MD, JD , national neurological injury attorney. Dr. Greg Vigna, MD, JD, states, "Pfizer is now involved in a significant legal case in California State Court in Alameda County concerning the known increased risk of meningiomas associated with Depo-Provera. The negligence alleged against the prescribing physicians centers on their failure to discontinue Depo-Provera or Medroxyprogesterone after our client was diagnosed with a cerebral meningioma, which we believe led to a recurrence of the meningioma after resection and to the development of multiple meningiomas. The literature is clear that this drug is mutagenic, and that other birth control medications exist that are equally as effective as Depo-Provera or Medroxyprogesterone without being mutagenic or carrying the same risk of causing meningiomas." What is a mutagen as defined by Merriam-Webster? “An agent as a chemical that tends to increase the frequency or extent of mutation." Read the definition of mutagen: https://www.merriam-webster.com/dictionary/mutagenic Dr. Vigna states, “The 2024 Roland study supports that this drug is mutagenic, showing an increased risk of meningiomas in women prescribed Depo-Provera or Medroxyprogesterone for one year or more. Both Roland and the 2018 study by Peyre describe the tendency of Depo-Provera or Medroxyprogesterone to cause a mutational shift in meningiomas, one associated with multiple skull-base tumors as well as an increased overall frequency of meningiomas.” Read Roland: https://www-bmj-com.libproxy1.nus.edu.sg/content/bmj/384/bmj-2023-078078.full.pdf Read Peyre: https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/pii/S0923753419354882 Dr. Vigna concludes, “We evaluate each case individually to determine whether a woman's claim is better filed in a state court where the medication was prescribed, rather than in the consolidated litigation in Florida, which now includes more than a thousand cases. It is important to examine why physicians continue prescribing Depo-Provera and Medroxyprogesterone despite the literature linking them to this serious injury, especially when there is no actual benefit compared with other birth control medications that do not cause meningiomas." Vigna Law Group is a national litigation firm that focuses on neurological injuries caused by medical malpractice, mid-urethral slings, and harmful drugs, including Depo-Provera. He represents women with the Ben Martin Law Group , a national pharmaceutical injury law firm in Dallas, Texas. The attorneys are product liability and medical malpractice attorneys, and they represent neurological injuries across the country. Click here to learn more about meningioma resection. Watch Dr. Vigna’s episode on Depo-Provera: https://youtu.be/3XkVyKTgnpQ?si=tOdRt3otIoNjktAT Watch Dr. Vigna’s Tik Tok for more information on Depo-Provera: https://www.tiktok.com/@vignalawgroup?is_from_webapp=1&sender_device=pc Case Number: 25CV151521 SUPERIOR COURT OF THE STATE OF CALIFORNIA, FOR THE COUNTY OF ALAMEDA California Offices: 8939 S. Sepulveda Blvd., Suite 102, Los Angeles, CA 90045 2570 N. First Street, 2nd Floor, San Jose, CA 95131 931 10th Street, #962, Modesto, CA 95354 2281 Lava Ridge Court, Suite 200, Roseville, CA 95661 600 West Broadway, Suite 700, San Diego, CA 92101 Connecticut Office: 515 Centerpoint Drive, Suite #2212, Middletown, CT 06457 Greg Vigna, MD, JD Vigna Law Group +1 8178099023 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Patent Infringement

100 Deals associated with Medroxyprogesterone Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D00951	Medroxyprogesterone Acetate	L02AB02 G03AC06 G03DA02	DB00603

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Suppression of ovulation	Japan	Kyowa Kirin Co., Ltd.	11 Mar 2022
Pain	United States	Pfizer Inc.	04 Dec 2020
Contraception	United States	Pfizer Inc.	17 Dec 2004
Pregnancy	United States	Pfizer Inc.	29 Oct 1992
Breast Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Endometrial Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Prostatic Cancer	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Renal Cell Carcinoma	China	Xi'an Lijun Pharmaceutical Co., Ltd.	01 Jan 1982
Abortion, Habitual	Japan	Pfizer Japan, Inc.	25 Jan 1963
Abortion, Threatened	Japan	Pfizer Japan, Inc.	25 Jan 1963
Hypomenorrhea	Japan	Pfizer Japan, Inc.	25 Jan 1963
Infertility	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menorrhagia	Japan	Pfizer Japan, Inc.	25 Jan 1963
Menstruation Disturbances	Japan	Pfizer Japan, Inc.	25 Jan 1963
Amenorrhea	United States	Pfizer Inc.	18 Jun 1959
Endometrial Hyperplasia	United States	Pfizer Inc.	18 Jun 1959
Metrorrhagia	United States	Pfizer Inc.	18 Jun 1959

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Eczema	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Neurodermatitis	Phase 3	China	Tianjin Pharm Research Inst Pharm Co Ltd.	11 Dec 2019
Osteoporosis, Postmenopausal	Phase 1	-	Wyeth AB	01 Sep 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04669678 (EPIC, CTgov)	Phase 4	Medication interactions \| HIV Infections \| Contraception	110	Etonogestrel (Group 1 DOR + ETG)	nqhjdmtoch(mysviqglho) = dfxmdocwmo yzbicgjugj (lzavmpjstw, maauogdxim - mcroxraiyt) View more	-	08 Apr 2025
				Intramuscular depo-medroxyprogesterone acetate (IM DMPA) (Group 2 DOR + IM DMPA)	nqhjdmtoch(mysviqglho) = vtwupqjfla yzbicgjugj (lzavmpjstw, hxwanhpzon - momlbwgxwu) View more
NCMP-03 (SNO2024)	Not Applicable	Meningioma ER/PR	64	EstrogenroneProgesteroneon (Estrogen or Progesterone use)	ntzjiklgey(skjlhsujwx) = ocatmvxtys ajnqxsoium (soejrnmaxi )	Positive	11 Nov 2024
				ProgesteroProgesteronetion (Unopposed Progesterone only use)	ntzjiklgey(skjlhsujwx) = kalrkskphy ajnqxsoium (soejrnmaxi )
ASTRO2024	Not Applicable	Meningioma	-	Progesterone use	xbbbnukimp(lukmroqkuk) = byovztrpia capmblucow (jmilmdhauj )	-	01 Oct 2024
				Estrogenroneprogesteroneon (Estrogen or progesterone use)	xbbbnukimp(lukmroqkuk) = hrcgojjksv capmblucow (jmilmdhauj )
NCT02550067 (ECHO, Pubmed \| BMC Womens Health) Manual	Not Applicable	Contraception	398	Depot medroxyprogesterone acetate (DMPA-IM)	bfirochmos(pbxolikzjn) = nhzdpzaoag oquwidasll (pdkdwuehpz ) View more	Positive	08 Mar 2024
				copper intrauterine device	bfirochmos(pbxolikzjn) = gzrkqybbzc oquwidasll (pdkdwuehpz ) View more
FRI413 (ENDO2023)	Not Applicable	occlusions	84	Norethisterone	bsyssukqql(elkfdjptwr) = ulpttwmbll wxsdpguphk (mlsdchrrkr, 0 - 252)	-	05 Oct 2023
NCT05438277 (CTgov)	Phase 4	Shoulder Pain	421	MPA+Methylprednisolone (Methylprednisolone Acetate (MPA))	ndlqhwfism = aionczpqkf rtcoxjsxjr (ggydasfjoa, epwkeulcpv - iotxotztnv) View more	-	07 Mar 2023
				Triamcinolone Acetonide (TA) (Triamcinolone Acetonide (TA))	ndlqhwfism = vfqpwyuxbx rtcoxjsxjr (ggydasfjoa, yuwktxqrny - tpdshkyvfz) View more
NCT02550067 (Pubmed \| Clin Infect Dis)	Not Applicable	Herpes Simplex	4,062	Depot medroxyprogesterone acetate (DMPA-IM)	dyhayealeu(nqdbdkjrlk) = dqoirvlcgo eeshcwvhrr (didkehafhd )	-	10 Sep 2022
				Levonorgestrel (LNG) implant	dyhayealeu(nqdbdkjrlk) = tmftvbvjaq eeshcwvhrr (didkehafhd )
SGO2022	Not Applicable	Endometrial Carcinoma	-	Progestin retreatment	tsgwovajyd(fyooqtwxru) = egejjfbzqi xrvdsirpvh (hhfxamrllv ) View more	-	01 Aug 2022
NCT02122198 (CTgov)	Not Applicable	Cognitive Dysfunction \| Endothelial dysfunction \| Impairment of Executive Functions	17	Placebo (Placebo)	esblovflcu(jjypoiqjdw) = kydeghxccl dfkdyiwska (pdmfswlonv, 3.88) View more	-	10 Jan 2022
				Medroxyprogesterone+Estradiol+Leuprolide acetate (GnRH Agonist)	esblovflcu(jjypoiqjdw) = dmmsyifzxg dfkdyiwska (pdmfswlonv, 57.61) View more
NCT02550067 (ECHO, Pubmed)	Not Applicable	-	401	Depot Medroxyprogesterone Acetate Intramuscular Injection	mmbuicdidm(arvnzuieyv) = fnkbchnkix jrfkpzvutd (ftxbgjbyat )	-	01 Jan 2022
				Copper Intrauterine Device	mmbuicdidm(arvnzuieyv) = aisxicasgq jrfkpzvutd (ftxbgjbyat )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis